This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Biogen's Fampyra Conditional Approval Converted to Standard
by Zacks Equity Research
Biogen Inc. (BIIB) announced that the conditional marketing authorization for its drug Fampyra for improvement of walking in multiple sclerosis (MS) patients in the EU has been converted to a standard marketing approval.
Biotech Stock Roundup: Biogen Inks Deal to Boost Pipeline, Sangamo Soars on Pfizer Deal
by Arpita Dutt
Quite a few deals were announced this week including by companies like Biogen (BIIB).
Biogen (BIIB) Buys Stroke Candidate Cirara for $120M
by Zacks Equity Research
Biogen Inc. (BIIB) announced the acquisition of Remedy Pharmaceuticals' phase III candidate, Cirara for the treatment of large hemispheric stroke (LHI).
The Zacks Analyst Blog Highlights: Exxon Mobil, JPMorgan, Union Pacific, Biogen and Becton Dickinson
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Exxon Mobil, JPMorgan, Union Pacific, Biogen and Becton Dickinson
What's in the Cards for Ionis (IONS) this Earnings Season?
by Zacks Equity Research
Ionis Pharmaceuticals, Inc. (IONS) is scheduled to report first-quarter 2017 results on May 9. Last quarter, the company recorded a positive earnings surprise of 265%. Let's see how things are shaping up for this announcement.
Top Research Reports for May 4, 2017
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil (XOM), JPMorgan (JPM) and Union Pacific (UNP).
Acorda (ACOR) Q1 Loss Wider Than Expected, Revenues Miss
by Zacks Equity Research
Acorda Therapeutics, Inc. (ACOR) reported loss of 25 cents per share in the first quarter of 2017 (including the impact of stock-based compensation expenses), wider than the Zacks Consensus Estimate of a loss of 16 cents.
Lilly (LLY) Tops Q1 Earnings, Misses Sales, Shares Down
by Zacks Equity Research
Eli Lilly and Company (LLY) reported first-quarter 2017 adjusted earnings per share of 98 cents, which beat the Zacks Consensus Estimate of 96 cents by 2.1%.
Biogen (BIIB) Q1 Earnings & Sales Top, Spinraza Sales Strong
by Zacks Equity Research
Biogen Inc. (BIIB) reported better-than-expected results in the first-quarter of 2017. The company surpassed expectations both for earnings and sales.
Biogen (BIIB) Beats on Q1 Earnings and Revenue
by Zacks Equity Research
BIIB???s first quarter 2017 earnings were better-than expected. The company posted earnings of $5.20 per share while our consensus called for EPS of $4.97.
3 Key Factors to Look Out for in Biogen's Q1 Results
by Arpita Dutt
With Biogen (BIIB) set to report Q1 results tomorrow, here is a look at 3 key factors investors will be focused on apart from earnings and revenue.
Drug Stocks Q1 Earnings Releases on Apr 25: LLY, BIIB, NVS
by Zacks Equity Research
As the Q1 earnings season gets in full swing this week, we believe this quarter is on track to see the highest growth in almost three years.
What's in Store for Biogen (BIIB) this Earnings Season?
by Zacks Equity Research
Biogen Inc. (BIIB), a well-known name in the multiple sclerosis (MS) market, will report first-quarter 2017 results on Apr 25, before the market opens.
Bristol-Myers and Nordic Ink Biomarker Collaboration Deal
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) recently announced that it has inked a collaboration agreement with Nordic Bioscience, a Danish company specializing in biomarker technologies.
Biogen to License Alzheimer Candidate from Bristol-Myers
by Zacks Equity Research
Biogen Inc. (BIIB) recently announced that it has inked a deal to buy worldwide rights for Bristol-Myers Squibb's (BMY) anti-tau antibody, BMS-986168, for an upfront payment of $300 million.
AbbVie's Elagolix Meets Primary Endpoint in Phase II Study
by Zacks Equity Research
AbbVie Inc. (ABBV) along with Neurocrine Biosciences, Inc. (NBIX) announced positive results from a phase IIb study evaluating its pipeline candidate elagolix for reducing heavy menstrual bleeding in premenopausal women with uterine fibroids.
Acorda (ACOR) to Reduce Workforce, Focus on Product Pipeline
by Zacks Equity Research
Acorda Therapeutics, Inc. (ACOR) recently announced plans to reduce its workforce by approximately 20%.
Acorda's (ACOR) MS Drug Patents Invalidated, Shares Plunge
by Zacks Equity Research
Acorda Therapeutics, Inc.???s (ACOR) shares were down almost 21.5% after the U.S. District Court for the District of Delaware invalidated four patents of its key multiple sclerosis drug, Ampyra.
Roche's Ocrevus Wins FDA Approval for 2 Forms of Sclerosis
by Zacks Equity Research
Roche Holdings AG (RHHBY) announced that the FDA has approved Ocrevus (ocrelizumab) as the first and only drug for both relapsing and primary progressive forms of multiple sclerosis.
Biotech Stock Roundup: Amgen Down on Repatha Data, Nektar Surges on Pain Results
by Arpita Dutt
Biotech stocks were hit by the 2018 budget blueprint as well as news on companies like Amgen (AMGN) and Biogen.
3 Biotech Stocks That Are Broker Favorites
by Arpita Dutt
These 3 biotech stocks have been given a Strong Buy or Buy rating by 80% or more brokers and sport a favorable Zacks Rank #1 (Strong Buy) or #2 (Buy).
Alkermes Starts Phase III Study to Treat Multiple Sclerosis
by Zacks Equity Research
Alkermes plc (ALKS) announced the initiation of a new phase III study of pipeline candidate ALKS 8700.
Acorda's Four Ampyra Patents Upheld by PTAB, Shares Rise
by Zacks Equity Research
U.S. Patent and Trademark Office (USPTO) Patent Trials and Appeal Board (PTAB) upheld four patents of Acorda's key growth driver, Ampyra.
Biotech Stock Roundup: Trump Tweet Hits Biotech Stocks, Concert Gains on Vertex Deal
by Arpita Dutt
Biotech stocks felt the heat once again with President Trump tweeting about competition in the drug industry and lowering drug prices.
Repros (RPRX) Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Repros Therapeutics Inc. (RPRX) is expected to report fourth-quarter 2016 results this month.